Therapies that inhibit mTOR prolong progression-free survival and have been approved for use in multiple cancers, including renal cell carcinoma, neuroendocrine tumors, and advanced breast cancer, with trials ongoing in other malignancies [69,70,71,72]. Here, MTOR is linked to hereditary clear cell renal cell carcinoma.